Clinical Study
Electrophysiological Studies in Patients with Pulmonary Hypertension: A Retrospective Investigation
Table 1
Baseline characteristics.
| | All patients () | | (%) |
| Gender (f/m) | 28/27 (51/49) | Comorbidities | | Coronary heart disease | 10 (18.2%) | Unknown: 4 (7.5%) | History of MI | 5 (9.1%) | CABG | 6 (10.9%) | Arterial hypertension | 37 (67%) | Diabetes mellitus | 13 (23.6) | Medication | | Vitamin K-Antagonist | 40 (72%) | ASS | 10 (18.2%) | Beta-blocker | 21 (38.2%) | ACE inhibitor | 24 (43.6%) | AT1 blockers | 7 (12.7%) | Aldosterone antagonist | 24 (43.6%) | Diuretics | 44 (80%) | Amiodoaron | 10 (18.2%) | Calcium channel blocker | 3 (5.5%) | Digitoxin/Digoxin | 3/2 (5.5/3.6%) | Cardiac devices | | Cardiac pacemaker | 3 (5.5%) | Indication | Bradyarrhythmia absoluta (), sick sinus syndrome (), bradycardia/tachycardia syndrome () | ICD | 2 (3.6%) | Indication | Primary prevention |
|
|
MI: myocardial infarction, CABG: coronary artery bypass graft, ACE: angiotensin converting enzyme, AT1: angiotensin 1, and ICD: implantable cardioverter defibrillator.
|